| 产品编号 | bs-2531R |
| 英文名称 | NES/Kallikrein 10 |
| 中文名称 | 上皮细胞特异性蛋白1抗体 |
| 别 名 | Kallikrein 10; Breast normal epithelial cell associated serine protease; Kallikrein related peptidase 10; KLK 10; KLK10; KLK10_HUMAN; NES 1; NES1; Normal epithelial cell specific 1; Protease serine like 1; PRSS L1; PRSSL 1; PRSSL1. |
 |
Specific References (3) | bs-2531R has been referenced in 3 publications.
[IF=2.559] Cao XY et al. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC.Biochem Biophys Res Commun. 2018 May 15;499(3):584-593. IHC-P&WB ; Mouse&Human.
[IF=2.3] Li, Lei, et al. "Upregulated KLK10 inhibits esophageal cancer proliferation and enhances cisplatin sensitivity in vitro." Oncology Reports. WB ;
[IF=0] Wang et al. Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer. (2013) Cancer.Prev.Res.(Phila. 6:437-47 WB ; Human.
|
| 研究领域 | 肿瘤 细胞生物 信号转导 激酶和磷酸酶 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human (predicted: Mouse,Rat,Cow) |
| 产品应用 | WB=1:500-2000, IHC-F=1:100-500, IF=1:100-500, ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 31kDa |
| 细胞定位 | 分泌型蛋白 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human KLK10: 65-165/276 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Kallikrein 10 is a trypsin-like serine proteinase. Originally described from a subtractive library looking for genes that were down-regulated in breast cancer, kallikrein 10 was thought to be epithelial cell specific. Kallikrein 10 is reported to be up regulated in pancreatic cancer and ovarian cancer, but down regulated in testicular cancer and breast cancer, perhaps due to differential hormonal regulation, or tissue specificities. Breast cancer patients that had elevated kallikrein 10 had a worse prognosis, leading to speculation that kallikrein 10 might be protective in breast cancer, similar to the argument put forth for kallikrein 3 in prostate cancer. Kallikrein 10 is found in high levels in the pancreas and in lower levels in the tonsils, esophagus, skin, brain, testis and ovary. Biological fluids (breast milk, serum, seminal plasma, urine) contain kallikrein 10, the highest levels found in milk. The cerebral spinal fluid (CSF) contains Kallikrein 10, and was reported to be elevated in patients with Alzheimer’s disease. Endogenous inhibitors include kallistatin, protein-C inhibitor and 1-proteinase inhibitor, although Kallikrein 10 can be found complexed to a number of different proteinase inhibitors. Function: Has a tumor-suppressor role for NES1 in breast and prostate cancer. Subcellular Location: Secreted. Tissue Specificity: Expressed in breast, ovary and prostate. Similarity: Belongs to the peptidase S1 family. Kallikrein subfamily. Contains 1 peptidase S1 domain. SWISS: O43240 Gene ID: 5655 Database links: Entrez Gene: 5655 Human Omim: 602673 Human SwissProt: O43240 Human Unigene: 275464 Human KLK10是组织激肽释放酶基因家族的重要成员,是当前研究较热的肿瘤生物学标志物之一,在多种与内分泌相关的肿瘤中有较特异性的表达。 |
| 产品图片 |
Sample:
DU145(Human) Cell Lysate at 30 ug Primary: Anti-NES/Kallikrein 10 (bs-2531R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 31 kD Observed band size: 31 kD 
Sample:
MCF-7(Human) Cell Lysate at 30 ug Primary: Anti-NES/Kallikrein 10 (bs-2531R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 31 kD Observed band size: 31 kD |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
